Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG

MOR00208 (formerly Xmab5574)

Trial Locations (3)

St. Jude Children's Research Hospital, Memphis

Ohio State University Medical Center, Columbus

University of Texas M.D. Anderson Cancer Center, Houston